Those comments are standard for Aussie investors in biotech, but A$45m is chump change by US standards, and pharma have enormous war chests desperate for assets. Only invest in Aussie pharma on the basis that you can lose the lot. But timing of investment can make or break returns and timing now, IMO, is skewed in favour given managements recent comments on progress. If results meet expectations, phase II will probably be funded by a partner.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.142M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $4.1K | 2.05M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 21212359 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 5012918 | 12 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| 1AD (ASX) Chart |